| Page 1977 | Kisaco Research
 

Conor Begley

Co-founder
Tribe Dynamics

Conor Begley

Co-founder
Tribe Dynamics

Conor Begley

Co-founder
Tribe Dynamics
 

Jason Fiedler

Angel Investor

Jason graduated from the University of Pennsylvania and

received the Frederick H. Gloeckner Award in
Entrepreneurial Studies from The Wharton School. He
finished as the top undergraduate in the 2011 Wharton
Business Plan Competition and was one of two undergraduates
accepted into Wharton's on-campus incubator program for
student-run start-ups.

Jason Fiedler

Angel Investor

Jason Fiedler

Angel Investor

Jason graduated from the University of Pennsylvania and

received the Frederick H. Gloeckner Award in
Entrepreneurial Studies from The Wharton School. He
finished as the top undergraduate in the 2011 Wharton
Business Plan Competition and was one of two undergraduates
accepted into Wharton's on-campus incubator program for
student-run start-ups.

Upon graduating in 2011, Jason joined Insight Venture
Partners, a leading NYC-based growth equity fund focused on
internet and software businesses. Jason sourced Insight's
$26M investment in Smartsheet and was involved in Insight’s
investments in Pluralsight, Anaqua and Branding Brand.
Jason also helped manage recruiting for Insight’s Summer
Analyst Program across top-tier undergraduate universities.

In 2013, Jason moved to San Francisco and joined Uber as an
Operations Manager. Jason was responsible for launching and
managing three of Uber's first 100 markets, and was also
involved in the launch of UberRUSH and early experiments in
food delivery.

In 2015, Jason joined Red Sea Ventures and has since been
involved in everything from deal sourcing and diligence to
platform and portfolio management.

In addition to his professional career, Jason has been an
active participant in New Heights, a NYC-based charity that
combines basketball with academics and social support
services to boost high school graduation rates of innercity
youth. Jason was nominated and will be joining the
Junior Board at New Heights.
Jason grew up in Scarsdale, NY and nothing is more
important to him than family. He continues to play
recreational basketball, tennis, golf and indoor cycling.

 

Kelly Kovack

BeautyMatter

Kelly Kovack

BeautyMatter

Kelly Kovack

BeautyMatter
Showcase Presenter Profiles - UK 2018
 

Dr. Uwe Marx

CEO
TissUse

Trained in human biology and medicine, Dr. Marx is an accomplished entrepreneur and the scientific founder of TissUse, a spin-off of the Institute of Biotechnology of the Technische Universität Berlin, Germany. Over the course of his fruitful career in biotechnology, Dr. Marx has pursued ever more lifelike structures that can mimic human biology in vitro. Prior to founding TissUse, Dr. Marx was head of the “Multi-Organ-Chip” program at the University and the scientific co-founder at two successful Germany-based biotechs, ProBioGen AG and VITA 34.

Dr. Uwe Marx

CEO
TissUse

Dr. Uwe Marx

CEO
TissUse

Trained in human biology and medicine, Dr. Marx is an accomplished entrepreneur and the scientific founder of TissUse, a spin-off of the Institute of Biotechnology of the Technische Universität Berlin, Germany. Over the course of his fruitful career in biotechnology, Dr. Marx has pursued ever more lifelike structures that can mimic human biology in vitro. Prior to founding TissUse, Dr. Marx was head of the “Multi-Organ-Chip” program at the University and the scientific co-founder at two successful Germany-based biotechs, ProBioGen AG and VITA 34.

 
8-9 May 2018
Boston, USA
The influence of the microbiome on human health & disease has been a growing area of interest in recent years, however until recently the impact of the microbiome on the initiation, progression & treatment of cancer was unknown. In recent months research has uncovered the potential of the microbiome to improve cancer therapies and to be a useful tool for patient stratification and diagnostics. With a better understanding of the oncobiome there is the potential to improve patient outcomes and increase the efficacy of existing therapies and drugs.